Evaluation of tumour markers in patients with burning mouth syndrome

/Home/Burning Mouth Syndrome News and Information/Burning Mouth Syndrome Articles

Evaluation of tumour markers in patients with burning mouth syndrome

V Vučićević-BorasaCorresponding Author Informationemail address, L.J Lukinacb, A Cekić-Arambašina

Received 26 November 2002; accepted 27 November 2002.

Abstract

Burning mouth syndrome (BMS) is an enigmatous condition both for the patient and the clinician, and is diagnosed on the basis of the patient's symptoms when they have on examination an apparently healthy looking oral mucosa. A variety of local and systemic factors are known to contribute to burning mouth syndrome. Some authors reported that underlying malignancy could be a possible cause for BMS. In 23 patients with burning mouth syndrome as well as in 20 age, sex, and race matched healthy controls levels of tumour markers—CEA, CA 19-9, AFP, and CYFRA 21-1—were determined from sera. Immunoradiometric assay (IRMA) for detection of ELSA-CEA, ELSA-CA 19-9, ELSA 2-AFP, ELSA-CYFRA 21-1 (CIS bio international, ORIS group, France) was used. Statistical analysis showed no significant differences in the level of tumour markers CEA, CA 19-9, AFP, CYFRA 21-1 in patients with burning mouth syndrome when compared to the healthy controls. We can conclude that evaluation of tumour markers in patients with burning mouth syndrome is not useful and in terms of cost–benefit this investigation should not be performed in patients with burning mouth syndrome.

Volume 39, Issue 7, Pages 742-744 (October 2003)
© 2003 Elsevier Ltd. All rights reserved.